Purpose: Despite its widespread use, the positron emission tomography (PET) radiotracer 2-deoxy-2-[ 
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer types as it has an extremely poor 5-year survival rate of G 5 % [1] . This dismal prognosis is due in part to the asymptomatic progression of this malignancy in its early stages and the lack of adequate screening measures, resulting in 80-90 % of patients being diagnosed when the disease is already in an advanced, metastatic state. The ability to identify PDAC early in its development has been shown to improve outcome, particularly if the patient can be diagnosed while still eligible for potentially curative surgical resection [2] . At present, the most commonly utilised imaging modality for suspected PDAC is x-ray computed tomography (CT); however, it is now increasingly being used in conjunction with positron emission tomography (PET) to aid in early diagnosis and staging of this malignancy [3, 4] . The PET radiotracer 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG) is the standard clinical option for suspected PDAC; however, it has been shown to be largely ineffective for the detection of small (≤ 20 mm) pancreatic tumours, and in most cases inferior to conventional CT and magnetic resonance imaging (MRI) for the detection of liver, peritoneal and lung metastases. [ 18 F]FDG is also unable to distinguish focal mass-forming pancreatitis from pancreatic cancer in most cases [5] . These limitations strongly indicate the need for alternative biomarkers which arise during the early stages of PDAC formation that can be measured noninvasively by molecular imaging techniques.
Several gene expression analyses have shown that the transmembrane protein claudin-4 is upregulated increasingly throughout PDAC formation, including in the pre-invasive pancreatic intraepithelial neoplastic (PanIn) lesions which form before PDAC is established [6] [7] [8] [9] [10] . While this protein is also present in healthy bladder, breast, prostate and gastrointestinal mucosa, its expression levels in these environments are very low in comparison to those in pancreatic cancer tissues [11] . Claudin-4 therefore represents an attractive biomarker for the early detection of PDAC. The ability to detect claudin-4 upregulation may provide valuable diagnostic and staging information which would supplement conventional imaging procedures and impact on the clinical decision-making process.
In pursuit of a claudin-4 imaging agent, we and others have previously exploited the favourable binding characteristics of the bacterial ligand Clostridium perfringens enterotoxin (CPE). In 2013, Neesse et al. modified a C-terminal fragment of CPE (cCPE) with the fluorophore Cy5.5 (Cy5.5-GST-cCPE) and showed elevated uptake of this imaging agent in PanIn lesions and PDAC compared to normal pancreases in genetically engineered mouse models of pancreatic cancer [12] . As clinical applications of fluorescence imaging are limited due to considerable signal attenuation by tissue, we subsequently developed a cCPE derivative modified with the single-photon emission computed tomography (SPECT) radioisotope indium-111 ([ 111 In]cCPE-GST) [13] . Despite exhibiting a low binding affinity (1.93 ± 0.59 μM), this radiotracer revealed claudin-4-mediated tumour uptake in a variety of human cancer xenograft and genetically engineered models which were all found to have upregulated claudin-4 expression. However, overall tumour uptake was generally low, and we have since sought to investigate alternative claudin-4 targeting vectors with improved target affinity and specificity.
Radiolabelled antibodies, given their superior affinity and selectivity, have been used extensively as vectors for PET and SPECT imaging [14] . Here, we report the preclinical evaluation of an 111 In-labelled anti-claudin-4 monoclonal antibody with the aim of providing a new clinical tool for improving upon early detection of PDAC. As in vivo simulations of PDAC, we have used human pancreatic duct epithelioid carcinoma xenografts in mice, and also a wellvalidated, clinically relevant genetically engineered model of PDAC (KPC model) [15] that develops a spectrum of premalignant PanIN lesions which ultimately progress to PDAC.
Materials and Methods

Materials
All reagents were purchased from Sigma-Aldrich unless otherwise stated and were used without further purification. The chelating agent p-SCN-Bn-DTPA was purchased from Macrocyclics Inc. (Dallas, TX). Water was deionised using a Barnstead NANOpure purification system (Thermo Scientific) and had a resistance of 9 18.2 MΩ cm −1 at 25°C. Protein concentration measurements were made on a ND-1000 spectrophotometer (NanoDrop Technologies, Inc.). Instant thin-layer chromatography (iTLC) was performed on glass microfiber chromatography paper (Agilent Technologies), and strips were analysed with either a Bioscan AR-2000 radio-TLC scanner (Eckert & Ziegler) or a Cyclone Plus Phosphor Imager (PerkinElmer). Radioactivity measurements were determined using a CRC®-25R dose calibrator (Capintec, Inc.).
Antibodies
The human MAB4219 antibody (R&D Systems) was used as a targeting moiety for in vivo imaging of claudin-4 due to its ability to recognise an epitope in the first extracellular loop of the protein (aa Met29-Arg81). The reactivity of this antibody for both murine and human claudin-4 was confirmed by flow cytometry in claudin-4-expressing human Panc-1 and murine 4T-1 cells (see Suppl. S1).
The status of claudin-4 expression in cells and tissue was assessed by Western immunoblot and immunofluorescence (see supplementary information for full experimental protocols) using anti-claudin-4 antibodies 329400 and PA5-28830 (ThermoFisher Scientific), respectively, since MAB4219 does not perform in these techniques.
Radiolabelling
Modification of anti-claudin-4 mAb with p-SCN-Bn-DTPA and subsequent radiolabelling with indium-111 were Torres J.B. et al.: Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinomaconducted following methods described by Brom et al. [16] . In brief, to a solution of anti-claudin-4 MAB4219 (200 μg) or mouse IgG 2A (200 μg, MAB003, R&D Systems) in 0.1 M NaHCO 3 (pH 9, 100 μl, Chelex treated) was added 20 M equivalents of p-SCN-Bn-DTPA (245.6 μM) in anhydrous dimethyl sulphoxide. The reaction mixture was incubated at room temperature for 30 min with gentle shaking (450 rpm), and the excess p-SCN-Bn-DTPA was removed by Sephadex-G50 size exclusion chromatography (Sigma-Aldrich). The affinity of the DTPA-conjugated MAB4219 for claudin-4 was evaluated by flow cytometry in Panc-1 and HT1080 cells and compared to that of the unmodified antibody.
Indium-111 in 0.02 M hydrochloric acid (sourced from Mallinckrodt Pharmaceuticals) was added to a 2-mg/ml solution of the DTPA-modified antibody to achieve a ratio of at least 1 MBq to 1 μg. The reaction mixtures were incubated at room temperature for 1 h, and the radiolabelling efficiency was determined by iTLC using an eluent of 0.1 M sodium citrate buffer (pH 5.5). The crude reaction mixture was purified by Sephadex-G50 size exclusion chromatography, eluting with 100-μl fractions of phosphate-buffered saline (pH 7.4). 111 In]mIgG). SPECT/CT images were acquired using a nanoSPECT-CT scanner at 24, 48, and 72 h after injection. After the final imaging session, mice were euthanized by cervical dislocation, and selected organs, tissues and blood were removed. The amount of radioactivity in each organ was measured using a 1470 WIZARD gamma counter (PerkinElmer). Counts per minute were converted into MBq using a calibration curve generated from known standards. These values were decaycorrected to the time of injection, and the percentage of the injected dose per gram (% ID/g) of each sample was calculated.
In Vivo
Genetically engineered KPC mice (K-ras LSL.G12D/+ ; p53 R172H/+ ; PdxCre; male, 3-4 months old), which were found to be PDAC-positive by [ 18 F]FDG-PET and MRI screening, were also imaged by SPECT 72 h after 
Ex Vivo
After imaging, pancreatic cancer tissue from athymic BALB/ c nu/nu mice and KPC mice was flash-frozen with dry ice and stored at − 80°C overnight. Frozen tissue was sectioned (8 μm) using an OTF5000 cryotome (Bright Instruments Ltd). Tissue sections were thaw-mounted onto Superfrost PLUS glass microscope slides (Menzel-Glaser, Thermo Scientific) and allowed to dry at room temperature. The slides were then exposed to a storage phosphor screen (PerkinElmer, Super Resolution, 12.5 × 25.2 cm) in a standard X-ray cassette for 15 h. The phosphor screen was then imaged using a Cyclone® Plus Storage Phosphor System (PerkinElmer), and images were analysed with OptiQuant 5.0 (PerkinElmer) and ImageJ (NIH).
After autoradiography, claudin-4 levels and PDAC morphology in ex vivo tissue were characterised by immunofluorescence and haematoxylin and eosin (H&E) staining, respectively. Full experimental details for H&E staining are reported in the supplementary information.
Statistical Analyses
All statistical analyses and nonlinear regression were performed using GraphPad Prism (GraphPad Software). An extra sum-of-squares F test was used to compare equilibrium dissociation constants. One-or two-way ANOVA was used for multiple comparisons, with Tukey post-tests to calculate significance of differences between groups. All data were obtained in at least triplicate and results reported and graphed as mean ± standard deviation, unless stated otherwise.
Results
Target Validation
Western blot analysis of whole cell lysates (Fig. 1a) confirmed the expression of claudin-4 in the Panc-1 cell line. In contrast, claudin-4 could not be detected by Western blot in HT1080 cells. Immunofluorescence microscopy experiments on tissue sections obtained from Panc-1 or HT1080 xenograft tumours showed the differential claudin-4 status in these two cell lines that was maintained when transferred to an in vivo setting (Fig. 1b) .
Binding Affinity of DTPA-Anti-Claudin-4 mAb 
Imaging of Claudin-4 in Pancreatic Xenograft Tumours
Representative SPECT/CT images obtained at 24 Fig. 3a . Volume-ofinterest analysis revealed that uptake of [
111 In]anti-claudin-4 within claudin-4-overexpressing Panc-1 tumours increased over time, yielding uptake values of 9.5 ± 1.9, 14.7 ± 3.0 and 16.9 ± 4.5 % ID/ml at 24, 48 and 72 h post-injection (p.i.), respectively (Fig. 3b) 111 In]mIgG and therefore did not exceed the level of non-specific uptake resulting from the enhanced permeability and retention effect [17] . Taken together, these measurements strongly indicate that uptake of [ The overall in vivo biodistribution of [ 111 In]anti-claudin-4 is typical for a radiolabelled whole immunoglobulin. Due to its long residence time within the circulation and excretion via the hepatobiliary system, high signals can also be observed within the blood pool (heart and carotid arteries) and liver.
At 72 h p.i., the ex vivo biodistribution data (Table 1) In]mIgG in Panc-1 (0.6 ± 0.0; P G 0.001) and HT1080 (0.6 ± 0.2; P G 0.001) tumour-bearing mice. Similar conclusions were drawn for tumour-to-pancreas and tumour-to-intestines ratios, as derived from Table 1 .
Autoradiography of frozen xenograft sections (Fig. 3c Table S1 ). However, pancreas-toblood ratios were found to be similar for both tracers (~0. 35 (Fig. 4 and S2, respectively) . The presence of claudin-4 and PDAC lesions in the same tissue sections was confirmed by immunofluorescence and H&E staining, respectively. Interestingly, co-registration of autoradiography, immunofluorescence and H&E images showed a clear association between [
Imaging of Claudin-4 in KPC Mice
111 In]anti-claudin-4 uptake and claudin-4 expression in pancreatic ducts affected by PDAC (see Fig. 4 ).
Discussion
The progression of early preneoplastic PanIn lesions to invasive PDAC in humans is known to occur over several years, which provides a broad window of opportunity to diagnose this malignancy when interventional therapy is most likely to succeed [18] . The development of noninvasive imaging methods capable of detecting biomarkers associated with high-grade PanIn lesions would aid in the Uptake values are reported as % ID/g ± SD identification of patients most at risk of developing PDAC. In recent years, several biomarkers, signalling pathways and gene aberrations of PDAC have been discovered and are frequently the basis of novel targeted therapies in preclinical studies [8, 9, 19, 20] . However, examples of imaging agents directed against these early indications of pancreatic cancer are comparatively rare. Considerable efforts have been made to understand the role of claudin-4 in the development of PDAC and a variety of other cancer types. Gene expression analyses have revealed that claudin-4 is increasingly expressed in pancreatic cancer as it progresses into more advanced stages [21, 22] . Interestingly, several studies have demonstrated that claudin-4 protein expression is associated with decreased invasiveness and reduced metastatic potential, and it has been positively correlated with better prognosis in PDAC [6, 23] . Similar conclusions have been drawn regarding its involvement in colorectal cancer [24] , oesophageal squamous cell carcinoma [25] and gastric cancer [26] [27] [28] . Conversely, claudin-4 overexpression has been positively correlated with increased invasiveness [29] [30] [31] , metastasis [32, 33] , angiogenesis [34] and poor prognosis [35, 36] in several other cancer types, including breast [32, 35, 37, 38] , gastric [31, 36, 39] , lung [40] , ovarian [29, 34, 41, 42] , prostate [33] and uterine cancers [43] . Taken together, these results highlight the utility of claudin-4 overexpression not only as an early detection marker for many different cancers, but also as a cancer type-specific prognostic indicator.
Recent efforts to develop molecular imaging agents for the detection of claudin-4 have relied on the use of CPE fragments as targeting vectors [12, 13, 44] . While these approaches have shown great potential for delineating claudin-4 expression in tumour tissue and precancerous lesions in vivo, CPE-based imaging agents suffer from poor solubility, unknown immunogenicity and exhibit only moderate affinity and specificity for claudin-4.
Despite their slower kinetics, antibodies are considered an attractive alternative to CPE for molecular imaging of claudin-4 due to their superior target affinity and specificity. Foss and co-workers first reported specific binding of an iodine-125 radiolabelled anti-claudin-4 mAb to claudin-4 in subcutaneous and orthotopic xenograft models of PDAC in vivo by SPECT imaging [45] . However, the conspicuously low level of radioactivity in the blood (1.21 ± 0.77 % ID/g) at 48 h p.i. is atypical of an antibody and is suggestive of rapid dehalogenation which is a common issue with radioiodinated antibodies.
In the present study, we developed a refined antibodybased SPECT imaging agent for the delineation of claudin-4 expression in vivo. We selected a human anti-claudin-4 monoclonal antibody as a suitable targeting vector on the basis of its high binding affinity and specificity for human and murine claudin-4. Unlike the probe developed by Foss et al., this antibody was specifically modified with a bifunctional p-SCN-Bn-DTPA chelator in order to enhance the stability of the radioimmunoconjugate. Modification of 111 In]mIgG exhibited a more diffuse pattern of distribution (Fig. S2, supplementary information) 111 In]anticlaudin-4 mAb in the KPC model could also be the result of limited access to the tumour mass due to the presence of dense fibrous stroma, as well as non-specific accumulation of the radioimmunoconjugate in the liver and spleen. Further improvements in tumour-to-background ratios could be feasibly achieved by utilising a smaller antibody fragment which would undergo faster blood clearance and renal elimination. Pretargeted imaging strategies [46] may also offer an alternative solution, particularly as the high cell surface persistence of claudin-4 would render it a suitable candidate for this approach.
Conclusions
[ 111 In]anti-Claudin-4 mAb is a useful tool for the noninvasive SPECT imaging of claudin-4 which is a widely dysregulated and highly prognostic biomarker in pancreatic cancer. This imaging agent could therefore be used to aid in the early detection and characterisation of this malignancy.
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